RENAL MEDULLARY CARCINOMA
Clinical trials for RENAL MEDULLARY CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RENAL MEDULLARY CARCINOMA trials appear
Sign up with your email to follow new studies for RENAL MEDULLARY CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug sacituzumab govitecan, alone or combined with atezolizumab, can shrink rare tumors of the kidney, bladder, ureters, or penis. About 60 adults with specific rare cancer types will receive the drugs intravenously in 21-day cycles. The study…
Matched conditions: RENAL MEDULLARY CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Promising new therapy targets rare, aggressive cancers
Disease control Recruiting nowThis study tests whether the drug ubamatamab, alone or with cemiplimab, can help control rare cancers like renal medullary carcinoma and epithelioid sarcoma. About 40 adults with advanced or metastatic disease will receive the treatment to check safety and effectiveness. The goal…
Matched conditions: RENAL MEDULLARY CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy targets rare, aggressive kidney tumors
Disease control Recruiting nowThis phase 2 trial is testing two drugs—pembrolizumab (Keytruda) and enfortumab vedotin (Padcev)—in people with rare kidney cancers called collecting duct carcinoma and renal medullary carcinoma. About 23 patients with advanced or metastatic disease will receive the combination f…
Matched conditions: RENAL MEDULLARY CARCINOMA
Phase: PHASE2 • Sponsor: Giuseppe Procopio • Aim: Disease control
Last updated Jun 26, 2026 15:17 UTC